Petros Pharmaceuticals, Inc. (PTPI)
| Market Cap | 4.50M |
| Revenue (ttm) | 5.82M |
| Net Income (ttm) | -13.81M |
| Shares Out | 6.88M |
| EPS (ttm) | -6.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,633 |
| Open | 0.640 |
| Previous Close | 0.640 |
| Day's Range | 0.635 - 0.660 |
| 52-Week Range | 0.602 - 5.240 |
| Beta | 2.24 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+529.82%) |
| Earnings Date | May 13, 2024 |
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health... [Read more]
Full Company ProfileFinancial Performance
In 2023, PTPI's revenue was $5.82 million, a decrease of -2.83% compared to the previous year's $5.99 million. Losses were -$13.81 million, -31.06% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PTPI stock is "Strong Buy" and the 12-month stock price forecast is $4.0.
News
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients (Please see important safety information below) NEW YORK, NY / ACCESSW...
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding con...
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% ...
NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialis...
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Sta...
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc....
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
FDA requests meeting to review the Company's technology component and discuss further development and requirements NEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:P...
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction m...
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (...
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (N...
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTC Petros in discussi...
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC Status NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, ...
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRA NEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company...
Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announ...
Petros Pharmaceuticals Provides Letter to Shareholders
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provide...
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces toda...
Petros Pharmaceuticals Announces Capital Raise of $15 Million
Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRA NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the C...
Petros Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on December 1, 2022 NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq:PTPI), a le...
Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update
NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial r...
New FDA-Approved Labeling for Petros Pharmaceuticals' STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy
Expanded STENDRA Labeling Now Includes Data on a Significant Population of Men Not Previously Included Following Submission of Additional Clinical Trial Data NEW YORK, NY / ACCESSWIRE / October 25, 20...
Petros Pharmaceuticals to Participate in Two October 2022 Conferences
NEW YORK, NY / ACCESSWIRE / October 21, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offi...
Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy
Data Published in the "International Journal of Urology" Also Showed Secondary Endpoints, Such as Onset of action in 15 Minutes and Percentage of Patients Reaching Normal Erectile Function According t...
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022
NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial res...
Petros Pharmaceuticals Responds to Fraudulent Press Release
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today confirmed that a press release issued on July 28, 20...
Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share
Petros Pharmaceuticals to become a privately-owned company operating independently as part of Henry Crown and Company's healthcare platform